Novartis AG ADR (NVS)vsQiagen NV (QGEN)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
QGEN
Qiagen NV
$33.61
-1.21%
HEALTHCARE · Cap: $6.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2607% more annual revenue ($56.58B vs $2.09B). NVS leads profitability with a 23.9% profit margin vs 20.3%. QGEN appears more attractively valued with a PEG of 0.86. QGEN earns a higher WallStSmart Score of 73/100 (B).
NVS
Buy51
out of 100
Grade: C-
QGEN
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
-8.5%
Fair Value
$47.07
Current Price
$33.61
$13.46 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Keeps 20 of every $100 in revenue as profit
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 27.4%
Earnings expanding 21.9% YoY
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
3.7% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : QGEN
The strongest argument for QGEN centers on Profit Margin, PEG Ratio, P/E Ratio. Profitability is solid with margins at 20.3% and operating margin at 27.4%. PEG of 0.86 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : QGEN
The primary concerns for QGEN are Revenue Growth.
Key Dynamics to Monitor
NVS profiles as a declining stock while QGEN is a value play — different risk/reward profiles.
QGEN carries more volatility with a beta of 0.79 — expect wider price swings.
QGEN is growing revenue faster at 3.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
QGEN scores higher overall (73/100 vs 51/100), backed by strong 20.3% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Qiagen NV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?